JP6906811B2 - アルキル置換複素環化合物、そのための調製方法およびその医学的用途 - Google Patents
アルキル置換複素環化合物、そのための調製方法およびその医学的用途 Download PDFInfo
- Publication number
- JP6906811B2 JP6906811B2 JP2019515464A JP2019515464A JP6906811B2 JP 6906811 B2 JP6906811 B2 JP 6906811B2 JP 2019515464 A JP2019515464 A JP 2019515464A JP 2019515464 A JP2019515464 A JP 2019515464A JP 6906811 B2 JP6906811 B2 JP 6906811B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- cancer
- ethynyl
- dimethoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC*C(C(C(C#Cc1cc(OC)cc(*C)c1)=[N+])=CNCC(CC1)CCC1C(C=C)=O)=O Chemical compound CC*C(C(C(C#Cc1cc(OC)cc(*C)c1)=[N+])=CNCC(CC1)CCC1C(C=C)=O)=O 0.000 description 9
- WLPAQAXAZQUXBG-UHFFFAOYSA-N C=CC(N1CCCC1)=O Chemical compound C=CC(N1CCCC1)=O WLPAQAXAZQUXBG-UHFFFAOYSA-N 0.000 description 2
- NSOLQPRPCPDXPO-UHFFFAOYSA-N B=CCN1CCCC1 Chemical compound B=CCN1CCCC1 NSOLQPRPCPDXPO-UHFFFAOYSA-N 0.000 description 1
- RELMYZLTNPSHKJ-UHFFFAOYSA-N C=CC(N1CCCC1)O Chemical compound C=CC(N1CCCC1)O RELMYZLTNPSHKJ-UHFFFAOYSA-N 0.000 description 1
- IJJJSNBMFDDFBC-UHFFFAOYSA-N CC(OCCC#N)=O Chemical compound CC(OCCC#N)=O IJJJSNBMFDDFBC-UHFFFAOYSA-N 0.000 description 1
- OVRKATYHWPCGPZ-UHFFFAOYSA-N CC1CCOCC1 Chemical compound CC1CCOCC1 OVRKATYHWPCGPZ-UHFFFAOYSA-N 0.000 description 1
- RIZBLVRXRWHLFA-UHFFFAOYSA-N Cc1cc(OC)cc(OC)c1 Chemical compound Cc1cc(OC)cc(OC)c1 RIZBLVRXRWHLFA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610833890.3A CN107840842A (zh) | 2016-09-19 | 2016-09-19 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
| CN201610833890.3 | 2016-09-19 | ||
| PCT/CN2017/072570 WO2018049781A1 (zh) | 2016-09-19 | 2017-01-25 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529444A JP2019529444A (ja) | 2019-10-17 |
| JP2019529444A5 JP2019529444A5 (enExample) | 2020-03-05 |
| JP6906811B2 true JP6906811B2 (ja) | 2021-07-21 |
Family
ID=61618562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515464A Active JP6906811B2 (ja) | 2016-09-19 | 2017-01-25 | アルキル置換複素環化合物、そのための調製方法およびその医学的用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10710981B2 (enExample) |
| EP (1) | EP3517535B1 (enExample) |
| JP (1) | JP6906811B2 (enExample) |
| KR (1) | KR102783517B1 (enExample) |
| CN (2) | CN107840842A (enExample) |
| AU (1) | AU2017327954B2 (enExample) |
| CA (1) | CA3036594C (enExample) |
| ES (1) | ES2925212T3 (enExample) |
| MX (1) | MX390747B (enExample) |
| RU (1) | RU2729069C1 (enExample) |
| SG (1) | SG10202102822RA (enExample) |
| WO (1) | WO2018049781A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3894403A1 (en) | 2018-12-13 | 2021-10-20 | Intervet International B.V. | Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| KR20220120638A (ko) * | 2019-12-26 | 2022-08-30 | 베이징 이노케어 파마 테크 씨오., 엘티디. | (s)-1-(1-아크릴로일피롤리딘-3-일)-3-((3,5-디메톡시페닐)에티닐)-5-(메틸아미노)-1h-피라졸-4-카르복사미드의 결정질 형태 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JP2023528880A (ja) * | 2020-06-05 | 2023-07-06 | キネート バイオファーマ インク． | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
| BR112022024729A2 (pt) * | 2020-06-05 | 2023-02-28 | Kinnate Biopharma Inc | Inibidores de quinases do receptor do fator de crescimento de fibroblastos |
| CN115867547B (zh) * | 2020-08-27 | 2024-12-20 | 上海和誉生物医药科技有限公司 | 一种1h-吡唑-4-酰胺衍生物，其制备方法和应用 |
| EP4277903A4 (en) * | 2021-01-12 | 2024-11-27 | Beijing InnoCare Pharma Tech Co., Ltd. | PROCESS FOR PREPARING (S)-1-(1-ACRYLOYLPYRROLIDIN-3-YL)-3-((3,5-DIMETHOXYPHENYL)ETHINYL)-5-(METHYLAMINO)-1H-PYRAZOL-4-CARBOXAMIDE |
| CN115433190B (zh) * | 2021-06-02 | 2024-09-20 | 药雅科技(上海)有限公司 | 不可逆杂环化合物fgfr抑制剂的制备方法和用途 |
| CN114853739B (zh) * | 2021-02-03 | 2023-09-22 | 药雅科技(上海)有限公司 | 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途 |
| CN115043832B (zh) * | 2021-03-08 | 2023-08-22 | 药雅科技(上海)有限公司 | 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途 |
| MX2024005341A (es) * | 2021-11-03 | 2024-05-20 | Beijing Innocare Pharma Tech Co Ltd | Dispersion solida amorfa que comprende (s)-1-(1-acriloilpirrolidin -3-il)-3-((3,5-dimetoxifenil)etinil)-5-(metilamino)-1h-pirazol-4- carboxamida. |
| KR20240107172A (ko) * | 2021-11-16 | 2024-07-08 | 베이징 이노케어 파마 테크 씨오., 엘티디. | 두경부암을 치료하는 방법 |
| WO2023107870A1 (en) * | 2021-12-08 | 2023-06-15 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| MX2024006933A (es) * | 2021-12-08 | 2024-08-26 | Kinnate Biopharma Inc | Formas en estado solido de un inhibidor de fgfr. |
| AU2022407439A1 (en) * | 2021-12-08 | 2024-06-27 | Kinnate Biopharma Inc. | Treatment of cancer with an fgfr kinase inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| KR101124245B1 (ko) | 2002-06-27 | 2012-07-02 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
| CN1508130A (zh) | 2002-12-18 | 2004-06-30 | 中国科学院大连化学物理研究所 | N-苯基-n’-嘧啶基取代脲类衍生物的合成方法 |
| US7150894B2 (en) * | 2003-05-01 | 2006-12-19 | Kraft Foods Holdings, Inc. | Acid whey texture system |
| SI1761520T1 (sl) | 2004-06-23 | 2008-10-31 | Lilly Co Eli | Inhibitorji kinaze |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| WO2007059341A2 (en) | 2005-11-16 | 2007-05-24 | Sgx Pharmaceuticals, Inc. | Pyrazolothiazole protein kinase modulators |
| FR2908409B1 (fr) | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
| ES2364864T3 (es) * | 2006-12-21 | 2011-09-15 | Astrazeneca Ab | Acilaminopirazoles como inhibidores de fgfr. |
| US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| UA105005C2 (uk) * | 2008-06-16 | 2014-04-10 | Юніверсіті Оф Теннессі Рісерч Фаундейшн | Сполуки для лікування раку |
| FR2947546B1 (fr) | 2009-07-03 | 2011-07-01 | Sanofi Aventis | Derives de pyrazoles, leur preparation et leur application en therapeutique |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| EP3064204A1 (en) | 2010-03-01 | 2016-09-07 | GTx, Inc. | Compounds for treatment of cancer |
| EP2736514B1 (en) * | 2011-07-28 | 2017-10-18 | Nerviano Medical Sciences S.r.l. | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
| WO2013024427A1 (en) | 2011-08-16 | 2013-02-21 | Glenmark Pharmaceuticals S.A. | Novel urea derivatives as tec kinase inhibitors and uses thereof |
| CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| PT3023100T (pt) * | 2013-07-18 | 2019-05-29 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para administração intermitente de inibidor de fgfr |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| PE20160546A1 (es) | 2013-10-25 | 2016-05-26 | Novartis Ag | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4 |
| US10189813B2 (en) | 2015-03-25 | 2019-01-29 | Novartis Ag | Formylated N-heterocyclic derivatives as FGFR4 inhibitors |
-
2016
- 2016-09-19 CN CN201610833890.3A patent/CN107840842A/zh not_active Withdrawn
-
2017
- 2017-01-25 WO PCT/CN2017/072570 patent/WO2018049781A1/zh not_active Ceased
- 2017-01-25 MX MX2019003143A patent/MX390747B/es unknown
- 2017-01-25 JP JP2019515464A patent/JP6906811B2/ja active Active
- 2017-01-25 SG SG10202102822RA patent/SG10202102822RA/en unknown
- 2017-01-25 RU RU2019112046A patent/RU2729069C1/ru active
- 2017-01-25 KR KR1020197011454A patent/KR102783517B1/ko active Active
- 2017-01-25 CN CN201780057036.5A patent/CN109843873B/zh active Active
- 2017-01-25 CA CA3036594A patent/CA3036594C/en active Active
- 2017-01-25 ES ES17849992T patent/ES2925212T3/es active Active
- 2017-01-25 EP EP17849992.7A patent/EP3517535B1/en active Active
- 2017-01-25 AU AU2017327954A patent/AU2017327954B2/en active Active
-
2019
- 2019-03-14 US US16/353,806 patent/US10710981B2/en active Active
-
2020
- 2020-07-10 US US16/925,738 patent/US11059805B2/en active Active
-
2021
- 2021-07-07 US US17/369,850 patent/US11572353B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107840842A (zh) | 2018-03-27 |
| CN109843873A (zh) | 2019-06-04 |
| SG10202102822RA (en) | 2021-05-28 |
| MX390747B (es) | 2025-03-21 |
| JP2019529444A (ja) | 2019-10-17 |
| US20210332027A1 (en) | 2021-10-28 |
| KR102783517B1 (ko) | 2025-03-19 |
| CN109843873B (zh) | 2022-06-17 |
| AU2017327954B2 (en) | 2022-02-03 |
| US20190210997A1 (en) | 2019-07-11 |
| CA3036594C (en) | 2024-02-13 |
| KR20190052113A (ko) | 2019-05-15 |
| AU2017327954A1 (en) | 2019-05-02 |
| RU2729069C1 (ru) | 2020-08-04 |
| CA3036594A1 (en) | 2018-03-22 |
| US10710981B2 (en) | 2020-07-14 |
| US20200339541A1 (en) | 2020-10-29 |
| WO2018049781A1 (zh) | 2018-03-22 |
| US11059805B2 (en) | 2021-07-13 |
| EP3517535B1 (en) | 2022-06-29 |
| EP3517535A1 (en) | 2019-07-31 |
| MX2019003143A (es) | 2019-06-17 |
| US11572353B2 (en) | 2023-02-07 |
| ES2925212T3 (es) | 2022-10-14 |
| EP3517535A4 (en) | 2020-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6906811B2 (ja) | アルキル置換複素環化合物、そのための調製方法およびその医学的用途 | |
| RU2742485C2 (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| TWI751163B (zh) | Ｆｇｆｒ４抑制劑、其製備方法和應用 | |
| TWI826509B (zh) | 作為vanin抑制劑之雜芳族化合物 | |
| WO2017128917A1 (zh) | 吡唑稠环类衍生物、其制备方法及其在治疗癌症，炎症和免疫性疾病上的应用 | |
| CN116462677A (zh) | 一种多稠环prmt5抑制剂及其制备方法和应用 | |
| CN112939982A (zh) | 一种炔类杂环btk抑制剂及其制备方法和用途 | |
| CN113518779B (zh) | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 | |
| WO2020151589A1 (zh) | 酰胺基桥连杂环类化合物、及其组合物与应用 | |
| CN115490671A (zh) | Parp7抑制剂及其制备方法 | |
| CN115073469B (zh) | 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用 | |
| WO2020156283A1 (zh) | 炔基嘧啶或炔基吡啶类化合物、及其组合物与应用 | |
| WO2021197467A1 (zh) | 多靶点的抗肿瘤化合物及其制备方法和应用 | |
| CN107556366A (zh) | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 | |
| JP2023515729A (ja) | Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途 | |
| KR20260005244A (ko) | 치환된 티오펜 융합 유도체, 이를 포함하는 조성물, 및 의약품으로서의 이들의 용도 | |
| CN114853752B (zh) | Btk抑制剂吡啶并杂环类化合物的制备及其应用 | |
| CN110272416A (zh) | 吡唑并[3,4-c]吡啶-7-胺衍生物及其制备方法和应用 | |
| TWI727152B (zh) | 炔代雜環化合物、其製備方法及其在醫藥學上的應用 | |
| CN118420559B (zh) | 氘代噁二嗪酮化合物及其用途 | |
| RU2842251C2 (ru) | Гетероциклическое соединение, имеющее противоопухолевую активность, и его применение | |
| HK40002345B (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | |
| HK40002345A (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | |
| CN116478100A (zh) | 喹唑啉类衍生物及其制备方法和用途 | |
| CN115260156A (zh) | 作为jak2抑制剂的化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200127 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200127 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210326 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210525 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210623 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6906811 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |